Working Title: A Comparison of Approaches for Unplanned Sample Size Changes in Phase II Clinical Trials

By

Molly Olson

Thesis

Submitted to the Faculty of the

Graduate School of Vanderbilt University
in partial fulfillment of the requirements

for the degree of

MASTER OF SCIENCE

in

Biostatistics

May, 2017

Nashville, Tennessee

Approved (in progress):

Tatsuki Koyama, Ph.D.

Jeffrey Blume, Ph.D.

ACKNOWLEDGMENTS

TABLE OF CONTENTS

		Pa	age
AC	CKNOWLEDGMENTS	•	ii
LIS	ST OF TABLES	•	iv
LIS	ST OF FIGURES	•	v
AB	SSTRACT		vi
Ch	apter		
1	Introduction	•	1
2	Background	•	3
3	Deviation from Planned Sample Sizes In Second Stage	•	5
4	Deviation from Planned Sample Sizes in First Stage	•	8
	4.1 <i>Chang et al.</i> Alternative Designs and Adaptation		
5	Example	•	15
6	Results	•	18
7	Discussion and Conclusion	•	27
RI	EFERENCES		30

LIST OF TABLES

Tabl	le	Pa	age
5.1	Stopping rules for deviations from first stage planned sample size concrete		
	example		16
6.1	Attained design characteristics from deviation of Admissible II stage design		
	$(p_0 = 0.1, p_1 = 0.25, \alpha = 0.05, \beta = 0.20)$		22
6.2	Attained design characteristics from deviation of Simon's Optimal II stage		
	design $(p_0 = 0.5, p_1 = 0.65, \alpha = 0.05, \beta = 0.2)$		22
6.3	Attained design characteristics from deviation of Simon's Minimax II stage		
	design ($p_0 = 0.75$, $p_1 = 0.9$, $\alpha = 0.05$, $\beta = 0.2$)		23
6.4	Attained design characteristics from deviation of Simon's Optimal II stage		
	design $(p_0 = 0.05, p_1 = 0.25, \alpha = 0.1, \beta = 0.1)$		23
6.5	Attained design characteristics from deviation of Admissible II stage design		
	$(p_0 = 0.3, p_1 = 0.45, \alpha = 0.1, \beta = 0.1) \dots$	•	24
6.6	Attained design characteristics from deviation of Simon's Minimax II stage		
	design $(p_0 = 0.75, p_1 = 0.9, \alpha = 0.1, \beta = 0.1)$		24

LIST OF FIGURES

Figu	are	Page
6.1	Monte Carlo Simulation of Average Power of 20 Simon-like Designs when	
	Stage I Sample Size Deviates from Planned for Attained Designs $(n_t^{**} =$	
	$n_1^{**} + n_2$). Number of Simulations = 10	. 19
6.2	Monte Carlo Simulation of Average Power of 20 Simon-like Designs when	
	Stage I Sample Size Deviates from Planned for Attained Designs $(n_t^{**} =$	
	$n_1^{**} + n_2$) Number of Simulations = 10	. 19
6.3	Monte Carlo Simulation of Average Power of 20 Simon-like Designs when	
	Stage I Sample Size Deviates from Planned for Attained Designs $(n_t^{**} = n_t)$	
	Number of Simulations = 10	. 25
6.4	Monte Carlo Simulation of Average Type I Error Rates of 20 Simon-like De-	
	signs when Stage I Sample Size Deviates from Planned for Attained Designs	
	$(n_t^{**} = n_t)$ Number of Simulations = 10	. 26

ABSTRACT

Oncology phase II clinical trials are often used to evaluate the initial effect of a new regimen to determine if there is warrant further study in a phase III clinical trial. Simon's two-stage design is a commonly used design in specifying sample sizes and critical values in phase II oncology clinical trials. It is common, however, for attained sample sizes in these trials to be different than planned. In this thesis, we examine the problems in hypothesis testing for two stage phase II clinical trial designs when attained sample sizes differ from the planned design. We describe methods for redesigning trials when attained sample sizes that differ from planned and introduce a new method for redesigning a two stage clinical trial when the first stage sample sizes deviates from planned. These methods would primarily be used for prespecifying redesigns for the cases when the Simon-like design does not have planned accrual. We find that the Likelihood approach has more desireable characteristics for deviations from the planned design, though if one wishes to remain with a Frequentist approach, Olson and Koyama's method, an adaptation of a method that Chang et al. proposed, may also be appropriate.

Introduction

Oncology phase II clinical trials are often used to evaluate the initial effect of a new regimen to determine if further study is warranted in a phase III clinical trial [1, 2, 3]. Simon's two-stage design [2] is a commonly used design in phase II oncology clinical trials. Koyama and Chen [3] point out that it is common for actual sample sizes of these phase II trials to differ from the planned, pre-specified sample sizes. This happens due to unanticipated accruement speed or drop-out rates, and multi-center trials can be delayed in communication of enrollment and response information causing over enrollement. Currently, when attained sample sizes differ from planned, common practice is to treat the attained sample sizes as planned. Though, when acheived sample sizes differ from planned, testing the attained sample sizes as planned leads to invalid inference and hypothesis testing in these cases is not straightforward [1, 3]. Therefore, extensions of two-stage designs for hypothesis testing with unplanned sample size changes is essential.

Many Frequentist methods have been proposed to that handle unplanned sample sizes in the second stage while using the planned stage I sample size; however, our literature review found that only a few Frequentist methods handle unplanned sample sizes in stage I. Moreover, when focusing on deviations in sample sizes in the second stage, many proposed methods are adjusting inference procedures rather than proposing a redesign. Likelihood based designs, can be used to extend Simon's design, offer a nice solution to this problem because these designs offer flexibility in sample size without inflation of type I error rate. Because calculations of p-values are complicated when attained sample sizes are different from planned [3], we focus on methods that offer redesigns of a planned two-stage design that will be prespecified along with the planned design.

In this paper, we discuss the different methods for Simon's design when the attained

stage II sample size is different from planned and when attained sample sizes in both stages are different from planned. We review Simon-like designs in chapter 2 and illustrate redesign methods in chapters 3 and 4. In chapter 5, we review a concrete example from a Likelihood-based clinical trial, and in chapter 6, we present results of a numerical and theoretical study comparing Frequentist properties of approaches in the setting where stage I sample size differs from planned are presented.

Background

Simon's two stage designs for clinical trials are common designs for phase II oncology clinical trials [2]. In Simon's designs, the null hypothesis H_0 : $p \le p_0$ is tested against the alternative $H_1: p > p_1$, where p is the true response probability, p_0 is the highest probability of response that would indicate that the research regimen is uninteresting and p_1 is the lowest probability of response that would indicate that the research regimen warrants further investigation. Under these hypotheses, it is required that the type I error rate remain less than α and power remain above $1-\beta$. The general framework of Simon's design includes a sample size and critical value in each of the two stages. Let n_1 denote the first stage sample size, n_t the sample size at the end of the second stage, and let n_t be the sample size for the second stage; $n_2 = n_t - n_1$. Let r_1 be the first stage critical value, and r_t the critical value for the end of the second stage. Let X_1 be the number of successes observed in the first stage and X_2 be the number of additional success in the second stage so that $Z_1 \sim \text{Binomial}(n_1, p \text{ and } X_2 \sim \text{Binomial}(n_2, p).$ Also, let $X_t = X_1 + X_2$. In the first stage, n_1 subjects are enrolled. If r_1 or fewer subjects $(X_1 \le r_1)$ are successes, then the regimen is rejected and the trial is stopped for futility. If $r_1 + 1$ or more subjects are successful, then the trial continues to the second stage by enrolling n_2 additional subjects. If r_t or fewer out of the n_t subjects are successful $(X_t = X_1 + X_2 \le r_t)$, the treatment is considered to be futile, otherwise if $X_t \ge r_t + 1$ subjects succeed, the treatment is considered to be effective and will warrant further study.

Let b denote the binoial proability mass function, $\binom{n}{x}p^x(1-p)^{n-x}$ for x=1,2,...,n, and B denote the cumulative binomial distribution function $\sum_{i=0}^{x}\binom{n}{i}p^i(1-p)^{n-i}$. The probability of early termination (PET) with a given probability p in Simon's designs is given

by PET = $B(r_1, p, n_1) = P_p[X_1 \le r_1]$. The expected sample size for a given p is then $EN = n_1 + (1 - PET)n_2$, and the probability of rejecting a drug is then

$$PR(p) = B(r_1, p, n_1) + \sum_{x=r_1+1}^{min[n_1, r_t]} b(x, p, n_1)B(r_t - x, p, n_2)$$

It is required that $PR(p) \ge 1 - \alpha$ and $PR(p) \le \beta$. Given these constraints, it follows that unconditional power, UCP(p), given probability p, is given by

$$1 - PR(p) = 1 - \left(B(r_1, p, n_1) + \sum_{x=r_1+1}^{\min[n_1, r_t]} b(x, p, n_1)B(r_t - x, p, n_2)\right)$$
$$= \sum_{r_1+1}^{n_1} \left\{\sum_{x_2=r_t-x_1+1}^{n_2} b(x_2, p, n_2)\right\} b(x_1, p, n_1)$$

and $UCP(p_1) \ge 1 - \beta$ and $UCP(p_0) \le \alpha$

Simon introduced Optimal and Minimax criteria for selecting good designs [2]. An Optimal two-stage design is a two-stage design which minimizes the expected sample size under the null hypothesis (EN₀). while still satisfying the type I and type II error probability restrictions. The Minimax design will minimize the maximum sample size ($n_t = n_1 + n_2$). Jung *et al.* [4] introduced an extension of Simon's designs called Admissible designs that are considered a compromise between Optimal and Minimax. Admissible designs have similar maximum sample sizes as the minimax design and a similar EN₀ to the optimal design. These designs minimizes a straight line on the (n, EN)-plane, $q \times n + (1 - q) \times EN$, for some $q \in [0,1]$ [4]. Admissible designs satisfy (α , β) constraints and obtain an expected sample size somewhere between Optimal and Minimax designs. Admissible designs may be attractive because they have agreeable properties of both the Minimax and Optimal design. Simon's designs do not allow for early termination of the trial for efficacy [2], and we do not consider that design here. We focus this paper two-stage designs that are either Optimal, Minimax, or Admissible.

Deviation from Planned Sample Sizes In Second Stage

When over-enrollment occurs in the first stage, a straightforward solution is to perform an interim analysis on the planned number of first stage subjects, and adjust the testing procedure for a sample size in the second stage that may be different than planned. Likewise, it is also straightforward to simply wait for the appropriate enrollment for the first stage when under-enrollment occurs in the first stage. When over- or under-enrollment occurs in the second stage, it is also possible to adjust the testing procedure for the attained enrollment in the second stage. This is possible under the assumption of non-informative dropouts; stage I is concluded when the number of non-missing subjects is equal to the planned stage I sample size, and if over enrollment occurs in the first stage, those subjects will only be considered for the second stage analysis [3]. Literature exists describing point estimation of the response rate and p-values for hypothesis testing when stage two sample size is modified. A review of these methods can be found by Porcher et al. [1]. Among them is Koyama and Chen who have shown that the p-value in two-stage trials will depend on the design in addition to the attained data and is complicated in the setting of unplanned sample sizes [3], we only focus on methods that recalculate critical values for hypothesis testing, or redesigns, and will not focus on p-value calculations. Koyama et al. propose a method for inference when stage II sample sizes deviate from the planned stage II sample size [3]. Let $n_1, n_t, r_1, r_t, \alpha$ and β be the original design parameters as defined earlier. The authors let the first stage remain as planned and propose a redesign of the second stage. The authors first define conditional power, $A(x_1, n_2, p) = P_p[X_2 \ge r_t | X_1 = x_1]$. Using conditional power

evaluated at p_0 , they calculate a new critical value, r_t^* , by finding the maximum integer, r_t^* , such that $A^*(x_1, n_2^*, p_0) \leq A(x_1, n_2, p_0) \equiv P_{p_0}[X_2^* \geq r_t^* | X_1 = x_1] \leq P_{p_0}[X_2 \geq r_t | X_1 = x_1]$, where $X_2^* \sim \text{Binomial}(n_2^*, p_0)$ and n_2^* is the attained stage II sample size. This method will result in a controlled unconditional type I error rate because the new critical value gives a conditional type I error rate that is more conservative than the original conditional type I error rate, regardless of the observed stage II sample size. The authors comment that with the new critical value, r_t^* , the total number of positive responses required to reject the null hypothesis may be different because it is conditional on the result of the first stage.

Zeng *et al.* [5] proposed methodology that attempts to maximize the unconditional power while controlling for the type I error to calculate the stage II critical value for the attained second stage sample size. The authors define $r_2^*(x_1)$ to be the new second stage critical value when $x_1 \ge r_1$ and $r_t^* \equiv r_2^*(x_1) + x_1$. The second stage critical value will be the integer that maximizes

Power =
$$\sum_{x_1=r_1}^{n_1} {n_1 \choose x_1} p_1^{x_1} (1-p_1)^{n_1-x_1} \sum_{r_2^*(x_1)}^{n_2^*} {n_2^* \choose x_2} p_1^{x_2} (1-p_1)^{n_2^*-x_2}$$

while subject to

Type I error
$$= \sum_{x_1=r_1}^{n_1} \binom{n_1}{x_1} p_0^{x_1} (1-p_0)^{n_1-x_1} \sum_{\substack{r_2^*(x_1)\\r_2^*(x_2)}}^{n_2^*} \binom{n_2^*}{x_2} p_0^{x_2} (1-p_0)^{n_2^*-x_2} \leq \alpha$$

Though it is theoretically possible to find r_2^* , this problem doesn't have a closed form solution and the computation is exhaustive. Instead, the authors propose a normal approximation for the binomial random variable to ease the computation of power. That is,

$$\sum_{x_2=r_2^*(x_1)}^{n_2^*} \binom{n_2^*}{x_2} p^{x_2} (1-p)^{n_2^*-x_2} \approx 1 - \Phi\left(\frac{r_2^*(x_1) - n_2^* p}{\sqrt{n_2^* p(1-p)}}\right)$$

Substituting the above equation in for power and type I error, and using Lagrange multipliers and differentiating with respect to r_2^* , the problem is then equivalent to solving the equation

$$\left(\frac{1}{p_0(1-p_0)} - \frac{1}{p_1(1-p_1)}\right)r_2^{*2} - \frac{2n_2^*(p_0-p_1)}{(1-p_0)(1-p_1)}r_2^* + \frac{n_2^{*2}(p_0-p_1)}{(1-p_0)(1-p_1)} - 2n_2^*log\left(\frac{\lambda a(x_1)}{b(x_1)}\right)$$

where $a(x_1) = \binom{n_1}{x_1} p_0^{x_1} (1-p_0)^{n_1-x_1}$, $b(x_1) = \binom{n_1}{x_1} p_1^{x_1} (1-p_1)^{n_1-x_1}$, and λ is the Lagrange multiplier. The new critical value, r_2^* , is then $\max(0, \min(r_2^*, n_2^*))$. The authors suggest searching over a reasonable range of λ to find a λ such that the type I error is as closed to α as possible.

The authors performed a numerical study to compare their method to Koyama and Chen's. They find that, in almost all scenerios that were considered, Zeng *et al.*'s method had more power than Koyama and Chen and this is mostly because Koyama and Chen's method most often results in a lower type I error rate due to controlling of conditional type I error.

Deviation from Planned Sample Sizes in First Stage

A straightforward solution to under-enrollment in the first stage is to simply wait until the appropriate enrollment has been reached, hence, why there is little research for this problem. Because accruement of subjects can be unexpected in the first stage, and some situations require early evaluation of the first stage, it is imperative that methods are available to handle situations with attained sample sizes that differ from the planned sample size in stage I. Green and Dahlberg [6] and Chen and Ng [7] propose methods for inference when first stage sample sizes differ from those planned. Recall that p_0 is the highest probability of response that would indicate that the research regimen is uninteresting and p_1 is the lowest probability of response that would indicate that the research regimen warrants further investigation. The Southwest Oncology Group's standard approach is to use two-stage designs with a type I error rate of 5% and power of 90%. Southwest Oncology Group's inference method by suggesting to perform a hypothesis test on H_0 : $p = p_1$ versus $H_1: p < p_1$ in the first stage with type I error rate of 2% and concluding futility if the pvalue for this test is ≤ 0.02 . They then suggest testing H_0 : $p = p_0$ versus H_1 : $p < p_0$ in the second stage at the 0.05 level. The type I error rate of 2% corresponds to intuition regarding what constitutes evidence in favor of a hypothesis when the sample size is half of the planned total [6]. Green and Dahlberg extend the SWOG approach by applying this testing method on the attained design, but performing an unadjusted 0.055 level test of H_0 based on the attained total sample size at the second stage. The 0.055 level was chosen because of the discreteness of the binomial distribution and to acheive a type I error rate closer to

0.05. The authors demonstrated that this approach controls type I error and acheives desired power only in the limited situation when an overall α -level is 0.05, and it is unclear how this method would generalize to any α -level [8]. Li et al. also indicates that this limited approach, and particularly testing a hypothesis in the first stage with a type I error rate of 2%, is arbitrary and lacks theoretical justification. Chang et al. [9] also point out that Green and Dahlberg's designs can possibly be quite different than the planned design. Chen and Ng [7] suggest an approach to unplanned sample sizes by considering a range of sample sizes in both the first and second stages. They search these ranges for the Minimax and Optimal designs that satisfy error constraints using the average probability of termination for all possible first stage sample sizes and average expected sample size for all possible stage I and stage II sample size combinations that they consider [7]. Some limitations of this approach are that attained sample sizes may fall outside of the specified ranges, and only the average error probabilities are controlled rather than the actual error probabilities corresponding to the attained sample sizes. Thus, we consider new approaches to unplanned sample sizes in the first stage in both the Frequentist and Likelihood settings. In the interest of prespecifying designs, we focus on deviation from the planned sample size only in the first stage. It is impractical to prespecify limitless combinations of unplanned sample sizes in both the first and second stages.

4.1 *Chang et al.* Alternative Designs and Adaptation

Chang *et al.* [9] proposed an alternative design that is an extension of two-stage designs in order to handle unplanned sample sizes in both the first and second stages, though we only consider this extension for over- and under-enrollment in the first stage. This method calculates new critical values for attained sample sizes a priori, and thus one is able to create and pre-specify a new design based on a preferred Simon or Admissible design in defense of the events of unplanned sample sizes. We use this method to pre-specify new designs; that is, we calculate new critical values for different combinations of possible deviations in

sample sizes pre-attainment. Because it is desired to stay as closely to the original design as possible for financial and resource planning reasons, we investigate this method while maintaining the original second stage sample size (n_2) or original total sample size (n_t) . Again, let n_1 , n_t , r_1 , r_t , p_0 , p_1 , α , and β be the original, planned design parameters. Now, let n_1^{**} be the attained sample size for the first stage and $n_2^{**} = n_t - n_1^{**}$. Then, the two situations we consider are 1. $n_2^{**} = n_t + n_1^{**}$ and 2. $n_t^{**} = n_1^{**} + n_2$.

Chang *et al.* proposes a method for updating the stage I critical value based on the following β -spending function, where m is the attained sample size in the first stage.

$$eta(m) = \left\{ egin{array}{ll} eta_1 m/n_1 & ext{if } m \leq n_1 \ eta_1 + (eta - eta_1)(m-n_1)/n_2 & ext{if } m > n_1 \end{array}
ight.$$

Where $\beta_1 = P(X_1 \le r_1 | n_1, p = p_1)$ is the stage I type II error probability. We then find a new stage one critical value, s_1 , using this probability spending function such that $P(X_1 \le s_1 | n_1^{**}) \approx \beta(n_1^{**})$, where \approx means "closest to." After s_1 is selected, we then search for an integer for the second stage critical value, s_t , that satisfies

$$P(X_1 > s_1, X_t > s_t | n_1^{**}, m_2, p_0)$$

$$= \sum_{s_1}^{n_1^{**}} P(X_2 > s_t - X_1 | X_1 = x_1) P(X_1 > s_1)$$

$$\leq \alpha$$

where $m_2 = n_2$ or n_2^{**} . Chang *et al.*'s design can be used for any α -level and is flexible, close to the original design, and preserves the desired Frequentist type I error rate.

We modify Chang *et al.*'s method because we prefer to be conservative when straying from a desired Simon or Admissible design. We modify the design by selecting s_1 such that the new design's probability of early termination under the null (PET₀**) that is closest to the planned probability of early termination under the null, rather than using a type II error probability spending function. This is conservative because when the attained sample

size gets further from the planned sample size, the PET₀^{**} can get further from the original design's. By selecting the closest integer such that the PET₀^{**} is closest to planned, the probability of early termination is greater under large deviations and this method is consistent with Chang *et al.*'s. We select s_1 such that

$$P(X_1 \le s_1 | n_1^{**}, p_0) \approx P(X_1 \le r_1 | n_1, p_0)$$

We then select the stage two critical value, s_t , in the same fashion as Chang's design. Another option would be to be choose s_1 such that the probability of early termination under the null with the redesign is greater than or equal to the original design. In either case, the designs tend to be close when the attained sample size is close to the original, so we consider the case where the probability of early termination is closest to the original. We call this adaptation to Chang *et al.*'s design "Olson and Koyama's design"

4.2 Likelihood Design

Briefly, Likelihood methods in phase II designs use the likelihood ratio as a measure of evidence [10]. Define $L_n(p) \sim \text{Binomial}(n,p)$ to be $L_n(p) = P(X|p,n) = \binom{n}{x} p^x (1-p)^{n-x} \propto p^x (1-p)^{n-x}$. Here, the likelihood ratio is

$$LR_n = \frac{L_n(p_1)}{L_n(p_0)}$$

$$= \frac{p_1^{x_t}(1-p_1)^{n_t-x_t}}{p_0^{x_1}(1-p_0)^{n_t-x_t}}$$

$$\in \{[0,1/k], [1/k,k], [k,\infty)\}$$

We make the following decision at the conclusion of the study. If the $LR_n \in [0, 1/k]$, there is evidence for the null hypothesis, if $LR_n \in [1/k, k]$, there is weak evidence for either hypothesis, and if $LR_n \in [k, \infty]$, there is evidence for the alternative hypothesis. The probability of observing weak evidence is $PW_i = P(k_a \le LR_n \le k_b | H_i), k_a \le 1 \le k_b$, i=0 for null hypothesis.

esis and i=1 for alternative hypothesis, where k_a and k_b are benchmarks for description of evidence, the probability of observing strong evidence is

$$PS_i = \begin{cases} P(LR_n > k_b | H_i) & \text{if } i = 1 \\ P(LR_n < k_b | H_i) & \text{if } i = 0 \end{cases}$$

and the probability of obseving misleading evidence is

$$PM_i = \begin{cases} P(LR_n > k_b | H_i) & \text{if } i = 0 \\ P(LR_n < k_b | H_i) & \text{if } i = 1 \end{cases}$$

One advantage of a likelihood sequential design is that the universal bound of misleading evidence under the null hypothesis is $P(LR_n > k_b|H_0) \le \frac{1}{k_b}$ for any $n \ge 1$ when $\frac{1}{k_a} = k_b = k > 1$. This is advantageous because the change that the trial is stopped with misleading evidence under the null hypothesis at any point in time is less than or equal to $\frac{1}{k_b}$. As data accumulates, the probability of misleading evidence converges to 0, and this probability is often much less than $\frac{1}{k_b}$ [11] [12].

Ayers and Blume [10] consider a phase II two-stage design based on the likelihood. The Likelihood two stage design will enroll n_1 observations into the first stage. If we observe a likelihood ratio that is $k_{a_1} < LR_{n_1} < k_{b_1}$, where k_{a_1} and k_{b_1} are benchmarks for description of evidence in the first stage, we continue to the second stage. If we observe $LR_{n_1} \le k_{a_1}$, the study will stop for futility and if we observe $LR_{n_1} \ge k_{b_1}$, the study will stop for efficacy. In stage II, n_2 subjects are enrolled. If the $LR_{n_t} = LR_{n_1}LR_{n_2}$ is $k_{a_t} < LR_{n_t} < k_{b_t}$, where k_{a_t} and k_{b_t} are benchmarks at the end of stage II, then the study will conclude with weak evidence. The study will conclude with evidence for the alternative hypothesis if $LR_{n_t} \ge k_{b_t}$ and evidence for the null hypothesis if $LR_{n_t} \le k_{a_t}$. Because these designs are not restricted by error rates, this method offers favorable flexibility for unplanned sample sizes in the first stage. Likewise, one is able to add cohorts and the end of the second stage when there

proves to be weak evidence without penalization.

We compare Frequentist and Likelihood two-stage designs by adapting the Likelihood two-stage design to emulate conventional two-stage designs such as Optimal, Minimax, or Admissible designs with binary evidential zones: reject the null or fail to reject the null. In order to do this, one can start with a Simon-like design and redesign with a likelihood ratio approach by setting

$$\begin{aligned} k_{a_1} &= \left(\frac{p_1(1-p_0)}{p_0(1-p_1)}\right)^{r_1} \left(\frac{1-p_1}{1-p_0}\right)^{n_1} = \left(\frac{1-p_0}{1-p_1}\right)^{r_1-n_1} \left(\frac{p_1}{p_0}\right)^{r_1}, \\ k_{a_t} &= \left(\frac{p_1(1-p_0)}{p_0(1-p_1)}\right)^{r_t} \left(\frac{1-p_1}{1-p_0}\right)^{n_t} = \left(\frac{1-p_0}{1-p_1}\right)^{r_t-n_t} \left(\frac{p_1}{p_0}\right)^{r_t}, \\ k_{b_1} &= \infty, \\ k_{b_t} &= \infty, \end{aligned}$$

where n_1, n_t, r_1, r_2 are two-stage design parameters. Then, using k_{a_j} and k_{b_j} , we recalculate the critical values, s_1 and s_t , using

$$s_1 = \frac{log(k_{a_1}) - n_1^{**}log(\frac{1-p_1}{1-p_0})}{log(\frac{p_1(1-p_0)}{p_0(1-p_1)})}$$

$$s_t = \frac{log(k_{a_t}) - n_tlog(\frac{1-p_1}{1-p_0})}{log(\frac{p_1(1-p_0)}{p_0(1-p_1)})}$$

If s_1 or $s_t < 0$, they are set equal to zero. It is possible for these critical values to be less than 0 when the study design has low sample sizes and deviation from the planned sample size is extreme. Using these critical values, ...

add other likelihood properties here. i.e. how to calculate p(weak), p(strong), EN, and PET.

Ayers and Blume [10] show that the Likelihood designs preserve type I error rate and

are bounded by $\frac{1}{k_{b_l}}$ and are equal to $O_{p_i}\left(n^{-1/2}\right)$. Under the likelihood design, error rates tend to be less of an issue because the average of the error rates, $\frac{\alpha+\beta}{2}$, is minimized with the likelihood approach [10]. For the purpose of comparing methods, we do not consider the cases in which cohorts can be added after the second stage and let the total sample size or the second stage sample size remain as planned similar to the Frequentist approach. We also only consider Likelihood redesign methods to emulate Frequentist designs – to calculate new critical values – and do not consider pure Likelihood method two-stage design as formerly introduced.

Example

In order to compare these new Frequentist and Likelihood methods for deviation of sample size in the first stage, we first introduce an example. An actual phase II cancer clinical trial was designed using a Likelihood two-stage design. In order to stick to convention, the trial would only stop early for futility. The planned design parameters are $n_1 = 17$, $n_t = 41, r_1 = 7, r_t = 21, p_0 \le 0.4,$ and $p_1 \ge 0.6.$ This study design has an expected sample size of 25.6 and a probability of early termination of 64% under the null hypothesis. This is considered an Admissible design and meets the nominal type I error rate, $\alpha = 0.05$, and type II error rate, $\beta = 0.2$ where the actual type I error rate is 0.047. The authors provide alternative interim stopping rules for sample sizes that deviate from the planned design using the Likelihood approach to be shown in Table 5.1. These new designs have a probability of early termination under the null that exceed 50% and preserve type I and type II error rates. Using the original likelihood design, but varying n_1 , one can use Chang et al.'s method and Olson and Koyama's method, which uses probability of early termination criteria, to obtain similar results. The total sample size is equal to the planned total sample size, $n_t^{**} = n_t$ in this case. We compare attained methods' characteristics, in particular, type I error, power, probability of early termination under the null hypothesis, and expected sample size under the null hypothesis. We refer to the Likelihood redesign, Chang and Olson and Koyama redesigns as "attained methods."

This example illustrates the comprability of the three adapted design methods. Generally, the stopping rules between the Chang designs and the Likelihood design are the same when n_1^{**} when the probability of early termination under the null exceeds 50%. When $n_1 = 16$, the Olson and Koyama's design gives a more conservative critical value; this is

Table 5.1: Stopping rules for deviations from first stage planned sample size concrete example

Design	r_1	n_1	PET ₀	EN ₀	Likelihood ratio favoring H_0 that corresponds to Simon's futility stopping rule
Likelihood	6	16	53%	27.8	1/5.062
Chang <i>et al</i> .	6	16	53%	27.8	
Olson and Koyama	7	16	72%	23.1	
Likelihood	7	17	64%	25.6	1/3.375
Chang <i>et al</i> .	7	17	64%	25.6	
Olson and Koyama	7	17	64%	25.6	
Likelihood	7	18	56%	28	1/5.062
Chang <i>et al</i> .	7	18	56%	28	
Olson and Koyama	7	18	56%	28	
Likelihood	8	19	67%	26.3	1/3.375
Chang <i>et al</i> .	8	19	67%	26.3	
Olson and Koyama	8	19	67%	26.3	
Likelihood	8	20	60%	28.5	1/5.062
Chang et al.	8	20	60%	28.5	
Olson and Koyama	8	20	60%	28.5	
Likelihood	9	21	69%	27.2	1/3.375
Chang <i>et al</i> .	9	21	69%	27.2	
Olson and Koyama	9	21	69%	27.2	
Likelihood	10	23	71%	28.2	1/3.375
Chang <i>et al</i> .	10	23	71%	28.2	
Olson and Koyama	10	23	71%	28.2	

expected by design and because of the discreteness of the binomial distribution.

Results

We compare the methods of Chang *et al.*, Olson and Koyama, and the Likelihood by first selecting either an Admissible, Minimax, or Optimal two-stage design. We apply each method to deviation in first stage sample size of ± 10 . We suggest keeping the original total planned sample size or the original planned second stage sample size the same when utilizing Chang *et al.*'s and Olson and Koyama's methods. We choose to keep total sample size the same in our investigation because it results in a more similar design in terms of error rates than maintaining the original second stage sample size. Likelihood methods can result in increased type I error, which may be a concern in this constrained setting. We also see a parabolic decrease in power in Chang's method, which is not a fruitful result (Figure 6.1 and 6.2). We also suggest setting $n_t^{**} = n_t$ because this inhibits the ability to stray extremely far from the planned design. If one employs Chang *et al.*'s method, it can be radical in the first stage, and if the resulting probability of continuing is less than 0.05, it will be impossible to make a type I error. This will then reduce the two-stage design to a one-stage design.

We present results that are limited to our primary problem of interest in Tables 6.1 through 6.6. In each design table, the planned design is specified and the first stage sample size varies from planned, while maintaining the original total sample size. We compare attained methods characteristics, in particular, type I error, power, probability of early termination under the null hypothesis, and expected sample size under the null hypothesis. We refer to the Likelihood redesign, Chang and adaptation to Chang redesigns as "attained methods."

Table 6.1 displays a planned Admissible design with varying first stage sample size \pm

Figure 6.1: Monte Carlo Simulation of Average Power of 20 Simon-like Designs when Stage I Sample Size Deviates from Planned for Attained Designs $(n_t^{**} = n_1^{**} + n_2)$. Number of Simulations = 10.





Figure 6.2: Monte Carlo Simulation of Average Power of 20 Simon-like Designs when Stage I Sample Size Deviates from Planned for Attained Designs $(n_t^{**} = n_1^{**} + n_2)$ Number of Simulations = 10.



10. We notice that under low p_0 and p_1 , s_1 will vary between each method. Though, power and type I error are likely to be similar between and within each attained method, and expected sample size is also consistent. The Likelihood and Chang method are at risk of low probability of early termination, especially when the sample size is lower than planned. Table 6.2 shows an Optimal design when p_0 is 0.5. Between attained designs, particularly when there is overaccrual, s_1 is inconsistent. We particularly see a large difference when $n_1^{**} = n_1 + 10$ between the Likelihood and Olson and Koyama designs and the Chang design. The Likelihood design is anticonservative in type I error and conservative in type II error here, displaying a $\alpha^{**} > \alpha$ and $1 - \beta^{**} > 1 - \beta$. The Chang designs both have a conservative type I error for all sample size deviations, though Chang and Likelihood designs maintain higher power than Olson and Koyama's. Probability of early termination is closest to the original under Olson and Koyama's, and thus have a much lower expected sample size under the null hypothesis, with as much as a difference of approximately 23.

Table 6.3 displays results from a planned Minimax design when p_0 is larger than 0.5. Here, the Likelihood design has desireable properties with type I error and power consistently closed to the planned design for all deviations in sample size. Though, when the sample size is severely underaccrued, the probability of early termination nearly halves. The expected sample size is consistent between designs. The Chang designs stray from the planned nominal type I and type II errors when there is overaccrual. The PET₀ for the original Chang design varies significantly between deviations.

Table 6.4 through 6.6 display results for planned designs when $\alpha = \beta = 0.1$. Table 6.4 displays attained design characteristics for deviations in sample size when the planned first stage sample size is low. In all three attained designs, we see that as the attained sample size is lower than planned, there is a significant drop in power and a moderate to severe drop in type I error. The probability of early termination almost occurs with probability 1 when the attained sample size is $n_1^{**} = 1$. In practice, though, accrual lower than planned here is not practical. When there is overaccrual, attained design characteristics are not concerning.

Table 6.5 illustrates the similarity between attained designs when $p_0 = 0.3$. All designs and their deviations are relatively consistent in type I error, power, and PET₀. Though, the Olson and Koyama's design is most consistent in the probability of early termination with the planned design, but we see a conservative deviation in type I error for large overaccrual. Table 6.6 displays similar results as Table 5.3.

Table 6.1: Attained design characteristics from deviation of Admissible II stage design ($p_0 = 0.1, p_1 = 0.25, \alpha = 0.05, \beta = 0.20$)

				` '	` '	` '		` '	0.482 29.437	` '			
	gu	$1 - \beta^{**}$	0.671	0.754	0.797	0.819	0.830	0.803	0.821	0.831	0.836	0.827	0.834
	od Desig	$\boldsymbol{\alpha}_{*}^{*}$	0.034	0.040	0.043	0.045	0.046	0.043	0.045	0.046	0.047	0.046	0.047
	celiho	S_t	7	7	7	7	7	7	7	7	7	7	7
	Ξ	s_1	0	0	0	0	0	-	_	_	-	7	2
		$\overset{*}{\mathrm{EN}}^*_0$	19.742	24.738	28.603	20.079	23.602	26.725	29.437	31.754	28.032	30.345	32.406
		PET_0^{**}	0.590	0.478	0.387	0.697	0.621	0.549	0.482	0.420	0.648	0.592	0.537
	na Design	$1-\beta^{**}$	0.671	0.754	0.797	0.718	0.771	0.803	0.821	0.831	0.814	0.827	0.834
edesign	nd Koyan	$lpha_*^*$							0.045				
Re	on ar	S_{I}	7	7	7	7	7	7	7	7	7	7	7
	Ols	s_1	0	0	0	_	-	_	_	_	7	7	7
		$\overset{*}{\mathbf{E}}\overset{0}{\mathbf{N}}\overset{*}{\mathbf{N}}$	19.742	24.738	28.603	31.586	33.883	26.725	29.437	25.480	28.032	26.469	28.783
		PET_0^{**}	0.590	0.478	0.387	0.314	0.254	0.549	0.482	0.705	0.648	0.807	0.764
		$ -\beta^{**} $	0.671	0.754	0.797	0.819	0.830	0.803	0.821	0.792	0.814	0.785	0.810
	u								0.045				0.043
	Jesig	S_t	7	7	7	7	7	7	7	7	7	7	7
le Size	Chang I	s_1	0	0	0	0	0	-	1	2	2	ϵ	\mathcal{S}
Samp		n_1^{**}	5	7	6	Ξ	13	15	17	19	21	23	25
Attained Sample Size		EN_0	26.725	26.725	26.725	26.725	26.725	26.725	26.725	26.725	26.725	26.725	26.725
		PET_0	0.549	0.549	0.549	0.549	0.549	0.549	0.549	0.549	0.549	0.549	0.549
		r_t	7	7	7	7	7	7	7	7	7	7	7
Planned Design		r_1	-	_	-	-	-	-	-	-	-	-	1
ed D		u	41	41	41	41	41	41	41	41	41	41	41
Plann		n_1	15	15	15	15	15	15	15	15	15	15	15
_		p_1	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25
		p_0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1

Table 6.2: Attained design characteristics from deviation of Simon's Optimal II stage design ($p_0 = 0.5, p_1 = 0.65, \alpha = 0.05, \beta = 0.2$)

		$\overset{*}{\mathrm{EN}}^{*}_{0}$	44.472	45.950	47.370	48.745	50.083	43.719	45.494	47.214	48.886	50.516	52.110
		$\operatorname{PET}_0^{**}$	0.593	0.588	0.584	0.581	0.577	0.714	0.708	0.702	969.0	0.691	0.686
	_	$1 - \beta^{**}$	0.796	0.811	0.824	0.835	0.845	0.802	0.816	0.828	0.839	0.848	0.856
	od Design	$lpha_*^*$	0.048	0.050			0.053	0.047	0.049	0.050	0.051	0.053	0.054
	eliho	S_I	48	48	48	12 48	13 48	48	48	48	48	48	48
	ĽĶ	s_1	6	10	Ξ	12	13	15	16	17	18	19	20
		$\overset{*}{E}\overset{0}{N_{0}^{*}}$	33.622	35.859	37.966	39.967	41.880	43.719	45.494	47.214	48.886	50.516	52.110
		$\operatorname{PET}_0^{**}$	092.0	0.748	0.738	0.729	0.721	0.714	0.708	0.702	0.696	0.691	0.686
	Design	$1 - \beta^{**}$	0.685	0.716	0.743	0.765	0.785	0.802	0.816	0.793	0.803	0.811	0.818
design	l Koyama		0.037		0.042	0.044	0.045		0.049				
Ř	n and	S_I	48	48	48	48	48	48	48	49	49	49	49
	Olso	s_1	10	Ξ	12	13 48	14	15	16	17	18	19	20
		$\mathbf{E}\mathbf{N}_0^*$	56.528	45.950	47.370	48.745	41.880	43.719	45.494	47.214	43.592	45.518	47.398
				0.588									
		$1 - \beta^{**}$	0.815	0.811	0.788	0.798	0.785	0.802	0.816	0.793	0.782	0.798	0.813
	п	$lpha_*^*$	0.036	0.050	0.034	0.034	0.045	0.047	0.049	0.033	0.043	0.045	0.047
	Design	S_I	49	48	49	49	48	48	48	49	48	48	48
ole Size	Chang	s_1	∞	10	11	12	14	15	16	17	19	20	21
Sam		n_1^{**}	18	50	22	24	56	28	30	32	34	36	38
Attained Sample Size		EN_0	43.719	43.719	43.719	43.719	43.719	43.719	43.719	43.719	43.719	43.719	43.719
				0.714					0.714	0.714	0.714	0.714	0.714
_		r_t	48	48	48	48	48	48	48	48	48	48	48
esign		7	15	15	15	15	15	15	15	15	15	15	15
ed D		u	83	83	83	83	83	83	83	83	83	83	83
Planned Design		n_1	28	28 83 15 4	28	28	78	28	28	28	28	28	78
		p_1	0.65	0.65	0.65	0.65	0.65	0.65	0.65	0.65	0.65	0.65	0.65
				0.5									

Table 6.3: Attained design characteristics from deviation of Simon's Minimax II stage design ($p_0 = 0.75$, $p_1 = 0.9$, $\alpha = 0.05$, $\beta = 0.2$)

		**0 NE	9.517	27.033).494	8.892	7.882	7.499	0.332	0.383	0.902	3.132	3 945
				•		•	•	•	(-,	(-,			
			0.3	0.479	0.3	0.4	0.5	9.0	0.5	0.6	0.7	0.6	0.7
	_	$1-\beta^{**}$	0.805	0.800	0.809	0.807	0.805	0.802	0.810	0.810	0.810	0.810	0.810
	od Design	$\boldsymbol{\varsigma}_{*}^{*}$	0.050	0.050	0.051	0.051	0.050	0.050	0.051	0.051	0.051	0.051	0.051
	ikelihoo	S_I	33	33	33	33	33	33	33	33	33	33	33
	Ë	s_1	∞	10	Π	13	15	17	18	20	22	23	25
		EN_0^*	22.548	21.028	25.315	24.419	27.882	27.499	27.700	30.383	30.902	33.132	33.945
		PET_0^{**}	0.609	0.719	0.595	0.694	0.585	0.677	0.753	0.663	0.736	0.652	0.722
	Design	$1 - \beta^{**}$	0.763	0.738	0.792	0.782	0.650	0.802	0.798	0.650	0.650	0.650	0.650
Redesign	l Koyama	$lpha_*^*$	0.045	0.042	0.048	0.047	0.019	0.050	0.049	0.019	0.019	0.019	0.019
Re	n and	S_I	33	33	33	33	34	33	33	34	34	34	34
	Olso	s_1	6	11	12	14	15	17	19	20	22	23	25
		$\overset{*}{\mathrm{EN}}^{*}_{0}$	29.517	27.033	25.315	28.892	27.882	27.499	27.700	28.397	29.489	30.881	33.071
		PET_0^{**}	0.351	0.479	0.595	0.481	0.585	0.677	0.753	0.816	0.865	0.902	0.847
		$1-\beta^{**}$	0.648	0.800	0.792	0.650	0.650	0.802	0.798	0.791	0.782	0.770	0.650
	u	\pmb{lpha}_{*}^{*}	0.019	0.050	0.048	0.019	0.019	0.050	0.049	0.048	0.046	0.043	0.019
	Design	S_t	34	33	33	34	34	33	33	33	33	33	34
e Size	Chang	s_1	∞	10	12	13	15	17	19	21	23	25	26
Samp		n_1^{**}	12	4	16	18	50	22	24	56	28	30	32
Attained Sample Size		EN_0	27.499	27.499	27.499	27.499	27.499	27.499	27.499	27.499	27.499	27.499	27.499
		PET_0	0.677	0.677	0.677	0.677	0.677	0.677	0.677	0.677	0.677	0.677	0.677
_			33	33	33	33	33	33	33	33	33	33	33
esign		7.	17	17	17	17	17	17	17	17	17	17	17
Planned Design			l	39	39	39	39	39	39	39	39	39	36
Plan				22	22	22	22	22	22	22	22	22	22
		p_1	6.0	6.0	6.0	6.0	6.0	6.0	6.0	6.0	6.0	6.0	0.0
		p_0	0.75	0.75	0.75	0.75						0.75	0.75

Table 6.4: Attained design characteristics from deviation of Simon's Optimal II stage design ($p_0 = 0.05$, $p_1 = 0.25$, $\alpha = 0.1$, $\beta = 0.1$)

		$\overset{*}{\mathrm{EN}}\overset{0}{\overset{*}{\overset{*}{\overset{*}{\overset{*}{\overset{*}{\overset{*}{*$	2.150	5.995	9.298	12.128	14.546	16.606	18.353	19.830	21.073
		PET_0^{**}	0.950	0.857	0.774	869.0	0.630	0.569	0.513	0.463	0.418
	u	$1-\beta^{**}$	0.192	0.465	0.635	0.741	0.805	0.843	0.864	92870	0.882
	od Design	$lpha_*^*$	0.016	0.043	0.064	0.081	0.093	0.102	0.108	0.112	0.114
	eliho	S_t	2	7	7	7	7	7	7	7	7
	Liķ	s_1	0	0	0	0	0	0	0	0	0
		EN_0^*	2.150	5.995	9.298	12.128	14.546	16.606	18.353	19.830	18.454
		PET_0^{**}	0.950	0.857	0.774	0.698	0.630	0.569	0.513	0.463	0.792
	a Design	$1 - \beta^{**}$	0.200	0.484	0.635	0.741	0.805	0.714	0.727	0.733	0.842
esign	1 Koyama	α^{**} 1	0.050			0.081					860.0
Ked	n anc	S_t	0	_	7	7	7	3	3	3	7
	Olso	s_1	0	0	0	0	0	0	0	0	1
		**0 X:	.150	5.995	.298	12.128	1.546	909.91	18.353	6.539	18.454
		PET** E			0.774 9		0.630 12).829 16	3.792
		_	0.9	Ŭ	Ū	_			_	_	_
		$1-\beta^{**}$	0.20	0.484	0.635			3 0.714	0.727	5 0.802	3 0.842
	sign	$lpha_*^*$	0.050	0.097	0.06	0.081	0.093	0.028	0.02	0.086	0.098
4)	g De	S_{I}	0	1	2	2	2	ω	3	2	2
ple Size	Chang	s_1	0	0	0	0	0	0	0	1	1
Sam		n_1^{**}	-	\mathcal{E}	5	7	6	11	13	15	17
Attained Sample Size		EN_0 n_1^{**}	14.546	14.546	14.546	14.546	14.546	14.546	14.546	14.546	14.546 17
		${}^3\mathrm{T}_0$	530	530	530	530	530	530	530	530	530
		r_t	2	7	7	7	7	7	7	7	2
esign		7.	0	0	0	0	0	0	0	0	0
ž g		и	24	24	24	24	24	24	24	24	24
Planned Design		n_1	6	6	6	6	6	6	6	6	6
4		p_1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2 9 24 0 2
		p_0	0.05	0.05 0.2 9 24 0 2 0.0	0.05	0.05	0.05	0.05	0.05	0.05	0.05


Table 6.5: Attained design characteristics from deviation of Admissible II stage design ($p_0 = 0.3$, $p_1 = 0.45$, $\alpha = 0.1$, $\beta = 0.1$)

		Plan	Planned Design	esign	_		Attained Sample Size	Samp	le Size							Re	edesign									
									Chang	Design	J				Olsc	on and	1 Koyama	Design			Likelih	elihoo	d Design			
p_0	p_1		и	n r_1	r_t	PET_0	EN_0	n_1^{**}	s_1	S_t	$lpha_*^*$	$1-\beta^{**}$	PET_0^{**}	$\stackrel{*}{\mathrm{EN}}^*_0$	s_1	S_I	$lpha_*^*$	$1-eta^{**}$	PET_0^{**}	$\overset{*}{\mathrm{EN}}^{\overset{*}{*}}_{0}$	s_1	S_{t}	$lpha_*^*$	$1-eta^{**}$	PET_0^{**}	EN_0^*
0.3	0.45	37	72	Ξ	26	l		27	7	26	0.099	0.902	0.411	53.492	∞	26	l	0.871	0.577	46.020	7	56	0.099	0.902	0.411	53.492
0.3	0.45	37	72	Ξ	56	0.566		56	∞	56	0.097	0.897	0.479	51.416	6	56		0.862	0.636	44.652	∞	56	0.097	0.897	0.479	51.416
0.3	0.3 0.45		72	Ξ	56	0.566	52.181	31	∞	27	0.065	0.870	0.386	56.155	6	26	0.095	0.892	0.542	49.794	∞	56	0.101	0.910	0.386	56.155
0.3	0.45	37	72	Π	56	0.566	52.181	33	6	56	0.100	0.907	0.450	54.460	10	56		0.886	0.599	48.626	6	56	0.100	0.907	0.450	54.460
0.3	0.45	37	72	Π	56	0.566	52.181	35	10	56	0.099	0.904	0.510	53.132	10	56		0.904	0.510	53.132	10	56	0.099	0.904	0.510	53.132
0.3	0.45	37	72	Ξ	56	0.566	52.181	37	11	56	0.097	0.901	0.566	52.181	1	56		0.901	0.566	52.181	Ξ	56	0.097	0.901	0.566	52.181
0.3	0.45	37	72	Ξ	56	0.566	52.181	39	12	56	0.095	0.897	0.618	51.601	12	56		0.897	0.618	51.601	Ξ	56	0.101	0.912	0.482	56.108
0.3	0.45	37	72	Ξ	56	0.566	52.181	41	13	56	0.094	0.893	0.665	51.372	12	27		0.871	0.536	55.378	12	56	0.100	0.910	0.536	55.378
0.3	0.45	37	72	Ξ	56	0.566	52.181	43	14	56	0.091	0.889	0.708	51.466	13	56		0.908	0.587	54.967	13	56	0.099	0.908	0.587	54.967
0.3	0.45	37	72	11	26	0.566	52.181	45	14	56	0.098	906.0	0.635	54.864	13	27		0.875	0.509	58.264	13	56	0.103	0.915	0.509	58.264
0.3	0.45	37	72	=	56	0.566	52.181	47	15	26	0.097	0.904	0.678	55.050	41	27	990.0	0.874	0.559	58.028	4	26	0.102	0.914	0.559	58.028

Table 6.6: Attained design characteristics from deviation of Simon's Minimax II stage design ($p_0 = 0.75$, $p_1 = 0.9$, $\alpha = 0.1$, $\beta = 0.1$)


		$\stackrel{*}{\mathrm{EN}}^*_0$	34.602	33.023	35.129	34.113	33.416	33.121	35.124	35.255	35.757	37.372	38.199
						0.346							
	_	$1 - \beta^{**}$	0.900	0.900	0.900	0.900	0.900	0.900	0.900	0.900	0.900	0.900	0.600
	ikelihood Desigr	$\boldsymbol{\varsigma}_{*}^{*}$	960.0	960.0	960.0	960.0	960.0	960.0	960.0	960.0	960.0	960.0	0.096
	lihoc	S_I	11 33	33	33	33	33	33	33	33	33	33	33
	Like	s_1	Ξ	13	14	16	18	20 33 (21	23	25	26	28
		EN_0^*	30.199	28.774	31.765	30.964	33.416			35.255	35.757	37.372	38.199
		$\operatorname{PET}_0^{**}$	0.426	0.535	0.433	0.532	0.439	0.529	0.613	0.527	909.0	0.526	0.600
	n Design	$1 - \beta^{**}$	0.895	0.890	0.899	0.898	0.900	0.900	0.900	0.900	0.900	0.900	0.900
edesign	d Koyama Desig	$\boldsymbol{\alpha}_{*}^{*}$				0.095	960.0						
Re	n an	S_I	33	33	33	33	33	33	33	33	33	33	33
	Olson and	s_1	12	14	15	17	18	20	22	23	25	26	28
		$\stackrel{*}{\mathrm{EN}}^*_0$	34.602	33.023	31.765	34.113	33.416	33.121	33.255	33.805	34.727	35.960	37.441
		$\operatorname{PET}_0^{**}$	0.235	0.332	0.433	0.346	0.439	0.529	0.613	0.688	0.753	0.808	0.853
	-	$1 - \beta^{**}$	0.900	0.900	0.899	0.900	0.900	0.900	0.900	0.900	0.900	0.900	0.600
		$\pmb{\pmb{\varsigma}}^*_*$	960.0	960.0	0.095	960.0	960.0	960.0	960.0	960.0	960.0	960.0	0.096
	Desig	S_t	33	33	33	33	33	33	33	33	33	33	33
ole Size	Chang I	s_1	11	13	15	16	18	20	22	24	56	28	30
Sam		n_1^{**}	17	19	21	23	25	27	53	31	33	35	37
Attained Sample Size		EN_0	33.121	33.121	33.121	33.121	33.121	33.121	33.121	33.121	33.121	33.121	33.121
			-	_	_	0.529	0.529	0.529	0.529	0.529	0.529	0.529	0.529
_		r_t	33	33	33	33	33	33	33	33	33	33	33
Planned Design		7.	20	20	20	20	20	20	20	20	20	20	20
ned I		и	4	40	40	40	40	40	40	40	40	40	4
Plan		n_1	27	27 40 20 3	27	27	27	27	27	27	27	27	27
		p_1	6.0	0.9	0.9	6.0	6.0	6.0	6.0		6.0		0.9
		p_0	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75	0.75

Figure 6.3: Monte Carlo Simulation of Average Power of 20 Simon-like Designs when Stage I Sample Size Deviates from Planned for Attained Designs $(n_t^{**} = n_t)$ Number of Simulations = 10.



Figures 6.3 and 6.4 display Monte Carlo simulation results for type I error and power, respectively. The results are an average of 20 Simon-like designs with $\alpha = 0.05$, $\beta = 0.2$ and stage I sample size deviations with $n_t^{**} = n_t$ for each attained design method. Therefore, each point will be an average of attained type I error or power under different sample size deviations. We see that, on average, the Likelihood two-stage design has power above the nominal power and below the nominal alpha level for all sample size deviations ± 10 . Both Chang's and Olson and Koyama's methods are conservative in type I error for all sample size deviations, but are more likely to suffer in power.

Figure 6.4: Monte Carlo Simulation of Average Type I Error Rates of 20 Simon-like Designs when Stage I Sample Size Deviates from Planned for Attained Designs $(n_t^{**} = n_t)$ Number of Simulations = 10.



Discussion and Conclusion

This is perhaps surprising, because the two approaches use apparently different yard-sticks in comparing models: a P value from an F test is a probability based on a specific distribution that the test statistic will follow if the null hypothesis is true, while DAIC is simply based on the relative likelihood of the data under two different models, penalized by the disparity in model complexity. Nonetheless, deciding how small a P value is needed for us to prefer the more complicated model is equivalent to deciding how large a ratio of likelihoods indicates a convincing difference between models.

Deviations from the planned second stage sample size has been better studied than deviations from the planned first stage sample size. Many methods have been proposed on decision rules, and Koyama et al. had introduced a redesign when the first stage sample size is as planned. Because the calculation of a p-value in this case is more straightforward than when stage I differs, there may be less literature proposing redesigns. **NEW** One could calculate a p-value ignoring the sample paths for deviations in either the first or second stage, though. The p-value can be related to Akaike's Information Criterion and is then $P = \Pr\left(\chi_k^2 > -2log\left(\frac{L(\hat{\theta}_0)}{L(\hat{\theta})}\right)\right)$, where k is the number of parameters set equal to zero [13]. AIC and p-values use different yardsticks for measure of evidence, where the p-value is from an F test with the AIC is based on the likelihood of the data. Murtaugh [13] states that deciding how small the p-value is needed to determine statistical significance is similar to deciding how large of a likelihood ratio is required for a convincing difference. **End new** Here, we focused our investigation and results on deviations from the planned first stage sample size. One argument against redesigning these trials in the first place could be that researchers always have the option to simply wait until stage I sample size is met. In

practice, though, some ethical matters may arise that would give the researcher incentive to evaluate the first stage prematurely. For instance, if a new regimen appears to be more beneficial than historical treatments, but statistical requirements prevent new subjects from being enrolled until all currently enrolled subjects record responses, a researcher may consider this unethical. In this case, $n_1^{**} < n_1$ where n_1^{**} would be subjects who have recorded responses. Having a decision rule for a case such as this would alleviate some discomfort from both the researcher and statistician, though abuse of new decision rules would be discouraged.

A numerical study suggested that it may be desireable to redesign trials using the planned total sample size because it better controls type I error for all attained methods and power is closer to the nominal power, on average. Assuming that redesigns use the planned total sample size in the redesign, results from different Simon-like designs were presented. Chang and the Olson and Koyama methods primarily differ when there are extreme sample size shifts. This is most likely due to the nature of their methods and their primary goals of maintaining type II error spending or probability of early termination. Recommending the use of these designs in practice will depend on the desire of statistical approach of the researcher. If the researcher prefers to use a Frequentist approach in hypothesis testing, it may be recommended that the Olson and Koyama's approach is used because it results in higher average power across deviations. Because it may be of concern that researchers take advantage of the ability to deviate from the planned design, Olson and Koyama's method also penalizes deviation by resulting in a higher probability of early termination when there is underaccrual than Chang's method.

We do not consider redesigns when both the first and second stage accrual are not as planned because if one is interested in prespecifying stopping criteria for sample size deviations, the number of combinations needed to be specified in order to prespecify the exact combination that will occur is unreasonable. Though, these attained designs are able to accommodate if this is desired. One advantage to the Likelihood design is that it is able to

add cohorts of subjects at the end of the second stage if weak evidence is obtained without threatening Frequentist properties such as type I error. Another advantage to the Likelihood approach is that inference is more straightforward because one is not concerned with error rates or p-values. Though we don't consider calculating p-values when stage I differs from planned, it would be complicated if one wished to do so, whereas Likelihood methods would not require this. Likelihood designs are also more generalizable. The Likelihood two-stage approach could be generalized easily to three stages, whereas the Chang designs would not be able to generalize. In this paper, though, we are very much constraining the Likelihood design and not taking full advantage of its natural characteristics. One could simply use a pure Likelihood design and avoid Frequentist issues altogether.

A main concern that we have with redesigning trials for unplanned sample sizes is that researchers could take advantage of the these new stopping criteria and stray from the planned design too often. It is for this reason that one may consider adapting Chang's design using a very conservative rule in the first stage and have the probability of early termination under the null always be higher than planned. When deviations are extreme, especially where there is underacrrual, evaluating the trial early would be highly penalized by potentially having a very high probability of early termination. Overall, intentional early or late evaluation of the first stage without sound reason is highly discouraged and will not result in optimal statistical properties.

REFERENCES

- [1] R. Porcher and K. Desseaux, "What inference for two stage phase II trials?," *BMC Medical Research Methodology*, vol. 12, p. 117, 2012.
- [2] R. Simon, "Optimal two-stage designs for phase ii clinical trials," *Controlled Clinical Trials*, vol. 10, pp. 1–10, 1989.
- [3] T. Koyama and H. Chen, "Proper inference from simon's two-stage designs," *Statistics In Medicine*, vol. 27, pp. 3145–3154, 2008.
- [4] S.-H. Jung, Y. Lee, K. Kim, and S. L. George, "Admissible two-stage designs for phase ii cancer clinical trials," *Statistics In Medicine*, vol. 23, pp. 561–569, 2004.
- [5] D. Zeng, F. Gao, K. Hu, C. Jia, and J. Ibrahim, "Hypothesis testing for two-stage designs with over or under enrollment," *Statistics in Medicine*, vol. 34, pp. 2417– 2426, 2015.
- [6] S. Green and S. Dahlberg, "Planned versus attained design in phase ii clinical trials," *Statistics in Medicine*, vol. 11, pp. 853–862, 1992.
- [7] T. Chen and T. Ng, "Optimal flexible designs in phase ii clinical trials," *Statistics in Medicine*, vol. 17, pp. 2301–2312, 1998.
- [8] Y. Li, R. Mick, and D. Heitjan, "A bayesian approach for unplanned sample sizes in phase ii clinical trials," *Clinical Trials*, vol. 9, pp. 293–302, 2012.
- [9] M. Chang, Y. Li, and Q. An, "Alternative designs for phase ii clinical trials when attained sample sizes are different from planned sample sizes," *Biometrics and Biostatistics*, vol. 6, p. 229, 2015.
- [10] D. Ayers and J. Blume

- [11] J. Blume, "Personal communication," Spring 2016.
- [12] J. Blume, "How often likelihood ratios are misleading in sequential trials," *Communications in Statistics Theory and Methods*, vol. 37, no. 8, pp. 1193–1206, 2008.
- [13] P. A. Murtaugh, "In defense of p-values," *Ecology*, vol. 95, pp. 617–621, 2014.